Table 2.
The demography, clinical data and mNGS of 4 cases
| Case No. | Signs | Corneal scrapings | mNGS | Duration of treatment | Treatment | Prognosis |
|---|---|---|---|---|---|---|
| 1 | Diffuse, multifocal, rough, punctate, protruding corneal epithelial lesions; conjunctival hyperemia; Nipple reactions |
Giemsa staining (+); Modified Ziehl-Neelsen staining (+) |
(+) E. hellem |
85 days | 0.02% PHMB + 0.5% fluconazole + 0.1% sodium hyaluronate + oral albendazole | cured |
| 2 | Multifocal, rough, punctate, protruding corneal epithelial lesions; conjunctival hyperemia; Follicular reaction | - |
(+) E. hellem |
90 days | 0.02% PHMB + 0.5% fluconazole + 0.1% sodium hyaluronate + oral albendazole | cured |
| 3 | Diffuse, multifocal, rough, punctate, protruding corneal epithelial lesions; Conjunctival hyperemia |
Giemsa staining (+); Calcofour white staining (+) |
(-) | 60 days | 1% tacrolimus, 0.02% PHMB + 0.1% sodium hyaluronate | cured |
| 4 | Diffuse, multifocal, rough, punctate, protruding corneal epithelial lesions; Conjunctival hyperemia | Giemsa staining (-); Calcofour white staining (+) |
(+) E. hellem |
125 days | 0.5% fluconazole + 1% tacrolimus + 0.02% PHMB, oral albendazole | improved |
mNGS: Metagenomic next-generation sequencing. PHMB: polyhexamethylene biguanide